Background and aims: Understanding the determinants of Crohn's disease (CD) patients' health-related quality of life (HRQOL) may facilitate interventions that improve HRQOL. Therefore, we systematically assessed determinants of HRQOL in adult CD patients. Methods: The databases PubMed, EMBASE, the Cochrane Library, PsycINFO and CINAHL were searched for English abstracts, related to socio-demographic, psychological, clinical and treatment-related determinants of HRQOL in CD disease. Two independent reviewers extracted study characteristics and assessed the methodological quality according the criteria of Hayden et al. The main outcome was the number of studies showing a statistically significant association between the above-mentioned determinants and HRQOL. A meta-analysis was performed to quantify the relationship between disease activity and HRQOL. Results: Of the 2060 articles identified, 29 eligible studies were included. The majority of studies were cross-sectional and had a moderate to high quality. Data on psychological determinants were scarce. Work disability, increased disease activity, number of relapses, corticosteroid treatment and hospitalization rate were significantly associated with a lower HRQOL in the majority of included studies. Biological treatment positively influenced HRQOL. The pooled data on the association between disease activity and HRQOL resulted in a weighed mean correlation coefficient of − 0.61 (CI − 0.65 to − 0.57). Conclusions: HRQOL of adult CD patients is consistently determined by markers of active disease, including work disability, increased disease activity, number of relapses, biological treatment and hospitalization rate. As disease activity contributed to only 37% of HRQOL, there remains a need for additional, possibly modifiable, determinants. These determinants may refine possibilities to improve HRQOL.
Introduction
Crohn's disease (CD) is a chronic, progressive and potentially disabling disease. CD patients often deal with unpredictable and potentially debilitating symptoms, including diarrhoea, fatigue and urgency. In addition, they require long-term treatment with frequent adverse effects, the need of surgery and hospitalizations. 1 Therefore, CD patients report a lower HRQOL compared with healthy individuals. 2 HRQOL represents the functional effect of an illness and its consequent therapy upon a patient, as perceived by the patient. It encompasses several dimensions of life, including physical functioning, psychosocial functioning, role functioning, mental health and general health perceptions. 3 HRQOL is determined by socio-demographic, clinical and psychological and treatment-related determinants. 4, 5 Although disease activity is an important determinant of HRQOL in CD, even asymptomatic patients report a lower HRQOL, suggesting a role for other determinants. 6, 7 A comprehensive understanding of the above-mentioned determinants of CD patients' HRQOL may facilitate clinicians in clinical decision making, defining risk groups and allowing more accurate prediction of HRQOL. 8 This latter is especially relevant when choosing between two interventions with an equal clinical efficacy or when treating asymptomatic patients. 9 In two previous reviews, clinical determinants (mainly disease activity) and psychosocial determinants of HRQOL in CD have been meticulously described -however none have performed a systematic search strategy. 4, 5 This may have resulted in an incomplete retrieval of articles, thereby biasing results. In addition, the methodological quality of included studies has not been ascertained, making it difficult to interpret and compare results.
Therefore, we conducted a systematic review to assess and critically appraise the socio-demographic, clinical, psychological and treatment-related factors determining HRQOL in adult CD patients.
Material & methods
This systematic review was conducted in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. 10 
Search strategy (Supplementary; Table 1)
In collaboration with a librarian a search strategy was designed to identify articles concerning determinants of HRQOL in adult CD. PubMed (since 1966), EMBASE (since 1966), Cochrane Library (since 1996), PsycInfo (since 1960) and CINAHL (since 1982) were systematically searched for titles and abstracts published between inception date of the database and July 9th, 2012. The search strategy contained a combination of keywords (and their synonyms) and Medical Subject Headings (MESH)/EMTREES (in the case of EMBASE), including "Crohn's disease", "determinant", and "health-related quality of life". Both search strategy and search filter were modified for each database. The search strategy was supplemented with reference tracking from all included studies, relevant reviews and by using Web of Science.
Study selection
Titles and abstracts were identified as potentially eligible by two independent reviewers [KA, MH]. Titles and abstracts meeting the following inclusion criteria were selected for full-article review: 
Quality appraisal
A quality appraisal was performed in order to minimize bias and improve the reliability of our findings. Two reviewers [KA, MH] independently assessed the quality of each study by scoring 33 items divided into six sources of bias: study participation, study attrition, prognostic factor measurement, outcome measurement, confounding measurement and analysis (Supplementary; Table 2 ). 11 Bias was considered present if the majority of items within a potential source of bias pointed in this direction. The quality of the study was rated "high" if there was low or moderate risk of bias in all sources of bias. The quality of a study was rated "moderate" if there was a high risk of bias in one source. The quality of a study was rated "low" if there was a high risk of bias in at least two sources. Differences in quality appraisal between the reviewers were evaluated. When consensus could not be accomplished, agreement was obtained through discussions with a third arbiter [HF].
Data synthesis and analysis
Of all studies both reviewers extracted data concerning study characteristics and associations between determinants and HRQOL. All studies were reviewed for information about any reported socio-demographic, clinical, psychological and treatment-related determinants of both generic and diseasespecific HRQOL. When possible, determinants that seemed to describe similar characteristics were merged into one factor (e.g. disease duration and time since diagnosis). The main outcome was the frequency of studies showing a significant association between these determinants and total HRQOL. Determinants that were measured, but not included in the univariate or multivariate analysis, were classified as "not assessed". Disparities in results between the reviewers were discussed and if necessary, discussed with the arbiter.
Given the heterogeneity in the study design we stratified for cross-sectional studies and prospective studies (including randomized controlled trials) and separately assessed the associations within these strata. Given the relatively high number of cross-sectional studies, we further stratified for cross-sectional studies with either a low or moderate to high risk of bias.
Data on the association between disease activity and HRQOL were pooled by using R statistical software version 2.13.2. Heterogeneity of the studies was evaluated by using the Cochrane Q-test. 12 3. Results 3.1. Search strategy and selection criteria ( Fig. 1) The search strategy yielded 2060 published articles. Removal of all duplicates resulted in 1610 articles that were screened on title and abstract following the predefined inclusion and exclusion criteria. Incorrect study design and mixed IBD population were the main reasons for exclusion. In total, 1339 articles were excluded, leaving 217 for full-text screening. After full-text review, 27 studies were included in the systematic review. Consensus between the two independent reviewers [KA, MH] was reached in 83% of cases. Reference tracking retrieved two additional articles. 40, 41 3.2. Baseline characteristics (Table 2) Of the 29 studies, nine studies utilized data from three study populations. Four studies, of which three were published by Bernklev et al. [16] [17] [18] and one by Høivik et al. 29 , utilized data from the Inflammatory Bowel South-Eastern Norway (IBSEN) cohort. Høivik et al.'s study was considered as an original study as they analysed a subgroup of CD patients after ten years of follow-up, whereas the remaining three studies analysed data from IBD patients after five years of follow-up. 29 In addition, Casellas et al. published three studies utilizing data from the [22] [23] [24] Two Dutch studies utilized data from the same South-Limburg Cohort. 34, 35 Therefore, 24 original studies remained, which were suitable for extracting study characteristics. [13] [14] [15] [16] [19] [20] [21] [22] [25] [26] [27] [28] [29] [30] [31] [32] [33] [35] [36] [37] [38] [39] [40] [41] Most studies originated from Europe (15/24; 63%), [14] [15] [16] [19] [20] [21] [22] [28] [29] [30] [31] [35] [36] [37] 39 others were performed in the USA, 13, 25, 38 Canada, 33 Australia, 27 or in multiple nations worldwide. 26, 32, 40, 41 Most studies had a cross-sectional design (11/24; 46%). 20, 22, 25, 27, 30, 31, 33, [36] [37] [38] [39] Other types of study design were: cohort studies (5/24; 21%), 15, 16, 19, 29, 34 case-control studies (4/24; 17%) 13, 14, 21, 28 and randomized controlled trials (4/24; 17%). 26, 32, 40, 41 Seventeen out of 24 studies (67%) were multicentre studies, 14, 16, [19] [20] [21] [22] 26, 27, 29, 32, [35] [36] [37] [38] [39] [40] [41] and all studies recruited outpatients, of which nine studies (38%) also recruited inpatients. 19, 20, 22, 25, 26, 32, 33, 40, 41 Sample sizes varied between 52 and 628 patients, with a majority of females (3,576/5,735; 62%) and with mean/median ages ranging from 29 to 45 years. [13] [14] [15] [16] 19, 20, 22, [25] [26] [27] [28] [29] [30] [31] [32] [33] [35] [36] [37] [38] [39] [40] [41] Disease duration varied from six months to twenty years. 13, 14, 16, 19, 21, 22, [25] [26] [27] [28] [29] [30] [31] 36, 37, [39] [40] [41] With regard to the HRQOL measures, most studies employed both generic and disease-specific HRQOL measures (13/24; 54%). 14, 16, 19, 22, [25] [26] [27] 29, 30, 32, 37, 40, 41 The most frequently used disease-specific and generic measures were the IBDQ (15/24; 61%) 16, [20] [21] [22] [26] [27] [28] [29] [30] [31] [32] 35, 37, 40, 41 and the Short Form-36 (13/24; 54%), [14] [15] [16] 19, 22, 26, 29, 30, 32, 37, 38, 40, 41 respectively (Table 2) . Associations between determinants and HRQOL were mainly analysed using multivariate statistics (16/24; 75%) 14, 16, [19] [20] [21] [22] 25, 27, [29] [30] [31] [35] [36] [37] [38] [39] of which multiple linear or logistic regression analysis was the most frequently used statistical method (9/16; 56%). 16, [19] [20] [21] [22] 29, 30, 37, 39 3.3. Critical appraisal (Table 3,  Supplementary; Table 2) Although some studies utilized data from the same study population, [16] [17] [18] [22] [23] [24] 34, 35 studies differed regarding reporting and presentation of the results. Therefore, each of the 29 studies was assessed separately.
The overall interobserver agreement regarding quality assessment (risk of bias) was 90%. Twelve studies were considered to be of high quality ("low risk of bias"), 13, [16] [17] [18] [20] [21] [22] [23] 29, 34, 37, 38 15 studies were considered to be of moderate quality, 14, 19, [24] [25] [26] [27] [28] [30] [31] [32] 35, 36, [39] [40] [41] and two studies were considered to be of low quality ("high risk of bias). 15, 33 With regard to each of the six sources of bias, methodological shortcomings most frequently observed were: no clear description of recruitment methods (item 1c, Supplementary; Table 2 ), no information about dropouts (item 2b), no information about missing data for prognostic factors (item 3d), no information about standardized methods and outcome measurement for all participants (item 4c), incomplete data for potential confounders (item 5a), and no description of a conceptual model, supporting the analytic strategy (item 6b).
Determinants of HRQOL
Instead of overall HRQOL, one study used different domains of HRQOL as outcome measures. 33 Therefore this study was excluded, leaving 23 studies for further analysis. [13] [14] [15] [16] [19] [20] [21] [22] [25] [26] [27] [28] [29] [30] [31] [32] [35] [36] [37] [38] [39] [40] [41] 3.4.1. Socio-demographic determinants (Fig. 2) For all studies reporting a significant association between any one socio-demographic determinant (except work disability) and HRQOL there were at least as many studies reporting no significant association between that determinant and HRQOL. As reported by four articles, female gender was found to be significantly associated with a lower HRQOL. 16, 19, 22, 37 Work disability was reported twice, 13, 16 smoking status (smoking versus non-smoking) was reported twice, 19, 35 and age once, 21 as having a significant impact on total HRQOL. Being female, of older age, being a smoker and reporting IBD-related work disability adversely affected HRQOL.
Psychological determinants
Two studies examined the association between psychological distress, personality traits and disease-specific HRQOL. Boye et al. found that "social conformity" (decent, keeping order, doing things right and keeping social norms at a high level) was significantly associated with HRQOL. 20 Van der Eijk et al. showed that psychological distress, including anxiety and depression, and the occurrence of stressful life events all had a significant negative impact on HRQOL. 39 
Clinical determinants (Fig. 3)
With regard to disease activity and the number of relapses, there were more studies reporting a significant than a non-significant association with HRQOL. HRQOL was negatively influenced by an increased disease activity in ten studies 16, 19, 21, 22, 27, 29, 34, 36, 37, 39 and by an increased relapse rate in two studies. 18, 22 Other clinical determinants found to be significantly associated with HRQOL were extra-intestinal manifestations 36 and shorter disease duration. 31 3.4.4. Treatment-related determinants (Fig. 4 ) With regard to biological treatment and CD-related hospitalizations, there were more studies reporting a significant than a non-significant association with HRQOL. HRQOL was negatively influenced by CD-related hospitalizations in two studies, 19, 22 whereas HRQOL was positively influenced by biological treatment, including infliximab, adalimumab, natalizumab and certolizumab in four studies. 26, 32, 40, 41 In four out of nine studies HRQOL was negatively associated with corticosteroid treatment. 18, 19, 34, 37 When stratifying for cross-sectional studies 20, 22, 25, 27, 30, 31, 33, [36] [37] [38] [39] and prospective studies 15, 16, 19, 26, 29, 32, 34, 40, 41 , it was found that female gender, work disability and increased disease activity were consistently associated with a lower HRQOL in both strata. Only prospective studies reported a significant association between disability and HRQOL 16 and between biological treatment and HRQOL. 26, 32, 40, 41 When stratifying for cross-sectional studies with either a low 20, 22, 37, 38 or moderate to high risk of bias, 25, 27, 30, 31, 33, 36, 39 no discrepancies were found regarding determinant-HRQOL associations between these strata.
Meta-analysis
Six studies reported a correlation coefficient for the association between disease activity and overall HRQOL and were included for meta-analysis. 17, 24, 27, 28, 31, 36 Although there was a slight difference in the instruments used to assess disease activity and HRQOL, data seemed comparable and thus eligible for pooling of results. In a random-effects model, the weighted mean correlation found was of − 0.61 (95% CI − 0.654 to − 0.5684). The total variability due to heterogeneity was 75.27% (p = 0.0016).
Discussion
This systematic review of 29 studies, including 24 original studies with a total of 5735 participants, is the first systematic review assessing the determinants of HRQOL in adult patients with CD. Overall, the methodological quality of these studies was moderate to high, indicating that there was a low to moderate risk of biased results. HRQOL was consistently impaired by work disability, increased disease activity, number of relapses and hospitalization rate. Biological treatment was significantly associated with an improved HRQOL. Disease activity contributed to 37% of patients' HRQOL. There was a paucity of psychological data, which precluded us from identifying consistent associations between psychological factors and generic or disease-specific HRQOL.
To date, two iterative reviews have carefully summarized data on determinants of HRQOL in the mixed IBD population. 4, 5 One review particularly assessed the influence of disease activity on HRQOL, 4 whereas the other assessed the influence of psychosocial factors on HRQOL. 5 In line with our results, Cohen et al. found that HRQOL was impaired in CD patients with clinically active disease, and that disease activity was negatively correlated with HRQOL. Contrary to our results, Cohen et al. also found a negative association between surgery and the HRQOL of CD patients. 4 This negative association was only reported in one study, assessing the long-term prognosis of CD patients. 21 Other included studies did not report this negative association. Possibly, in these studies the post-operative follow-up period was too short to reveal a decreased HRQOL. In addition, HRQOL appeared to improve shortly after surgery, but not in the long term. 42 This is consistent with the fact that in most studies disease activity eventually recurs after surgery. [43] [44] [45] Sainsbury et al. conducted a search for studies which evaluated psychological, social and demographic 97 Determinants of HRQOL in Crohn's disease 5 This remarkably high number of included studies is mainly attributable to including studies of mixed IBD populations and studies with small sample sizes (b 50 patients), which were excluded in our study. In their review, Sainsbury et al. found a number of psychological and social factors to be related with a lower HRQOL in IBD patients, including female gender, lower socioeconomic status, ethnicity and perceived stress. 5 In line with our results, female gender was associated with a lower HRQOL. Several hypotheses for this finding exist. Psychosocial factors may play a greater role in females than in males. 19 Others state that females have greater disease-related concerns and worries about being a burden of being treated differently as a result of their illness. 46 Furthermore, females are also more likely to report concerns related to attractiveness, body image and feeling alone. 33 Noteworthy, females also report poorer HRQOL than males across various chronic illnesses -including asthma, 47 rheumatoid arthritis 48 and diabetes 49 and even in the general healthy population. 50 The negative influence of low socioeconomic status, ethnicity and higher perceived stress on HRQOL in CD patients could not be corroborated in our study, as these factors were reported by any of the included studies.
Psychological factors, such as illness perceptions and psychological distress (anxiety and depression), were underrepresented in the included articles, but warrant further research. Previous studies in IBD have found that illness perceptions contributed to 4-21% of patients' HRQOL, in addition to socio-demographic and clinical determinants. [51] [52] [53] More importantly, as these illness perceptions are modifiable, they provide potential targets for HRQOL enhancing interventions. In addition, anxiety and depression are highly prevalent in IBD patients, and have been found to be related with HRQOL. 39, [54] [55] [56] HRQOL was significantly impaired by work disability in two out of three studies. Noteworthy, work disability rates of IBD patients range between 1.3 and 34%, 13, 16, [57] [58] [59] [60] [61] [62] [63] with even higher rates in CD patients under 40 years of age. 63 As work disability leads to a heavy psychosocial and financial burden for patients, all efforts should be made to prevent work disability and to help work disabled patients back into the labour market.
Although we found a negative association between corticosteroid treatment and HRQOL in four out of nine studies, this finding should be interpreted with caution. First of all, this negative association was mainly based on cross-sectional studies, thereby, a potential positive or negative influence of corticosteroid treatment on HRQOL over time could not be determined. 20, 35, 38 Furthermore, not all studies appropriately corrected for disease activity, making it impossible to determine an independent association between corticosteroid treatment and HRQOL. 19, 38 It is known that corticosteroids are frequently associated with specific side effects, including cosmetic side effects and sleep and mood disturbances, with a possible negative effect on HRQOL. 64 However, whether these corticosteroid-specific side effects are responsible for the negative association between corticosteroid use and HRQOL remains a matter of debate. As HRQOL measures have been available in IBD management since the early 1980s, appropriate studies assessing the influence of conventional immunosuppressants, such as thiopurines and methotrexate, on CD patients' HRQOL were lacking. The available evidence from our analyses that HRQOL is positively influenced by biological treatment is relatively strong, as this evidence was mainly based on prospective randomized studies. 26, 32, 40, 41 Further non-randomized prospective studies are warranted to validate the positive impact of biological treatment on HRQOL in daily clinical practice.
Our study has several important strengths. The strength of the association between any of the determinants and HRQOL was assessed, indicating which of the variables significantly contributed to the HRQOL of CD patients. In addition, evidence on the determinants of HRQOL in CD is systematically summarized and critically appraised, showing all evidence available and revealing areas in which further research is required. As stated in the Introduction, a comprehensive understanding of the determinants of HRQOL may guide clinical decision making. Important clinical decision, such as top-down versus step-up therapy, ileocolonic resection versus anti-TNF therapy and anti-TNF mono-therapy versus combination anti-TNF plus thiopurine therapy, should ideally be based on this kind of evidence, as these decisions may have significant consequences to patients' daily lives.
Our study has some limitations as well. As we included studies with heterogeneous sample sizes, study designs, determinant and outcome measures, we were unable to quantify the relationships between other determinants, besides disease activity, and HRQOL. Although the pooled association between disease activity and HRQOL was relatively strong, this finding should be interpreted with caution as the meta-analysis indicated significant heterogeneity across the included studies. Furthermore, as we excluded abstracts and unpublished studies, publication bias cannot be completely ruled out. However, as most of the available and reviewed studies had a moderate to high quality, we feel that the contribution of unpublished studies would be minimal. Of note, all randomized controlled trials received financial support by a pharmaceutical company, which might suggest publication bias. However, none these companies were involved in the data analysis.
In conclusion, determinants that were found to consistently impact the HRQOL of adult CD patients, included markers of active disease such as work disability, clinical disease activity, increased relapse rate, biological treatment and hospitalization. Unfortunately, these determinants are not very helpful for clinicians when dealing with asymptomatic CD patients or when choosing between treatments with a comparable clinical efficacy (for example clinical remission). As disease activity contributed to only 37% of HRQOL, there remains a need for additional, possibly modifiable, determinants. Therefore, in order to improve our understanding of HRQOL and to facilitate clinical decision making, more long-term prospective data on, preferably, modifiable determinants of HRQOL are highly needed. Ultimately, this will improve HRQOL in an important subset of patients, leading to a decrease in health care and society costs.
